Form 4: MAIA Biotechnology Director Acquires Stock Options

MAIA Biotechnology, Inc. Director Steven M. Chaouki acquired 20,865 stock options with an exercise price of $1.80 per share, vesting immediately.

Summary

• Steven M. Chaouki, a Director of MAIA Biotechnology, Inc., acquired 20,865 stock options.
• The options were granted on June 30, 2025, pursuant to the MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan.
• Each option represents the right to buy one share of common stock at an exercise price of $1.80.
• The stock options vest 100% on the date of the grant and are exercisable beginning as of that date.
• The options are set to expire on June 30, 2035.

Sentiment

Score: 7

Explanation: The acquisition of stock options by a director is generally viewed as a positive indicator of confidence in the company's future performance and aligns management's interests with shareholders.

Positives

• Director Steven M. Chaouki's acquisition of 20,865 stock options may signal confidence in MAIA Biotechnology, Inc.'s future performance.
• The immediate 100% vesting of the options provides the director with immediate equity interest, aligning their incentives with shareholder value.

Negatives

• No specific negative financial or operational information is disclosed in this Form 4 filing.

Risks

• No specific risks are detailed in this Form 4 filing, which primarily reports an insider transaction.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance.

Management Comments

• No direct management comments or quotes are provided in this Form 4 filing.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends.

Comparison to Industry Standards

• No specific comparisons to industry standards or benchmarks are provided in this Form 4 filing, as it details an individual insider equity grant.

Related Party Transactions

• The acquisition of stock options by Steven M. Chaouki, a Director, constitutes a related party transaction as it involves an insider of MAIA Biotechnology, Inc.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aligns their interests with shareholders, as the director's financial benefit is tied to the company's stock performance.

Next Steps

• No specific future actions, events, or milestones for the company are detailed in this Form 4 filing.

Key Dates

Keywords

MAIA Biotechnology, MAIA, Stock Options, Insider Transaction, Form 4, Equity Incentive Plan, Director Compensation, Steven M. Chaouki